Earnings Call · Q4 FY2022·2023-02-23

Q4 22EPS -0.72%·Rev n/aQ3 22EPS -19.20%·Rev n/aQ2 22EPS -2.31%·Rev n/aQ1 22EPS -76.58%·Rev n/a⚠ consensus missing

Intellia Therapeutics, Inc. NTLA

Ian Karp — Head of Investor Relations

John Leonard — Chief Executive Officer

David Lebwohl — Chief Medical Officer

Laura Sepp-Lorenzino — Chief Scientific Officer

Glenn Goddard — Chief Financial Officer

+0.1%1d on move date−0.5% vs SPY3d+1.2%5d+4.6%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NTLA calls or request research access.

More NTLA calls Browse calls Request research access